BIIB: TIME’s Best Invention Could Skyrocket Biogen!

Biogen's headquarters in Cambridge, Massachusetts. Overview – Leqembi’s Spotlight and Biogen’s Opportunity: Biogen Inc. (NASDAQ: BIIB) is a biotech company best known for its neurological and rare disease therapies. A recent catalyst for Biogen is Leqembi (lecanemab) – an Alzheimer’s drug co-developed with Eisai – which was selected as one of TIME’s Best Inventions of 2023. Leqembi is only the second FDA-approved treatment for Alzheimer’s and “may be the most effective,” slowing cognitive decline by 27% in trials (^[1]). The drug works by reducing amyloid plaques in the brain, though it can cause brain swelling in some patients (^[1]). This groundbreaking therapy is now fully FDA-approved (July 2023) with Medicare coverage, translating into $67 million in Q3 2024 global sales (including $39 M in the U.S.) (^[2]). Investors hope that TIME’s recognition foreshadows Leqembi’s commercial success – a potential blockbuster that could help “skyrocket” Biogen’s growth if adoption accelerates. However, Biogen’s outlook depends not only on Leqembi but also on managing its legacy drug declines and executing new launches in a competitive biotech landscape.

Front-run Buffett — get the miner & 4 moonshot picks

One large miner at a 43% discount + four small miners with potential for 10–100x over the decade.

Golden Anomaly Now

Get the name, ticker & my top four miners

Dividend Policy & Shareholder Returns: Biogen does not pay a dividend, and accordingly offers no dividend reinvestment plan (^[3]). This no-dividend stance is common among high-R&D biotech firms, as they prefer to reinvest cash into drug development or acquisitions. Instead of dividends, Biogen has occasionally returned cash via share buybacks – for example, a $5 billion repurchase authorization in 2019 (since completed) and prior programs in 2015 (^[4]). With zero dividend yield, income-focused investors get no direct payouts, unlike some large biotech peers (e.g. Amgen or Gilead) that initiated dividends once their growth matured. Biogen’s management has thus far prioritized pipeline investment and strategic M&A (such as the $6.5 B Reata acquisition in 2023 (^[5])) over starting a dividend. Absent a dividend, shareholders look for value through stock appreciation – something that Leqembi and other new products will be critical to drive.

Leverage and Debt Maturities: Biogen’s balance sheet carries moderate leverage with about $5.6 billion in long-term debt outstanding (^[6]). In mid-2025 the company refinanced its nearest maturity, issuing $1.75 B of new notes and using the proceeds to retire its $1.75 B, 4.05% notes due Sep 2025 (^[6]). The new 2025 Senior Notes were issued in three tranches: $400 M due 2031 at 5.05%, $650 M due 2035 at 5.75%, and $700 M due 2055 at 6.45% (^[6]) (^[6]). Thanks to this refinancing, Biogen now faces no significant debt maturities until 2030 – its next major tranche is $1.35 B of 2.25% notes due May 2030 (^[6]). Biogen also repaid a $650 M term loan in early 2024 from cash on hand (^[6]), further easing near-term obligations. Overall, the company has pushed out its debt schedule well into the 2030s-2050s, reducing refinancing risk. Biogen holds a solid liquidity buffer as well, with cash and equivalents of ~$2.8 billion as of mid-2025 (^[6]). This cash (~$2.8 B) versus debt (~$5.6 B) yields a net debt around $2.8 B, indicating a manageable leverage position for a company expected to generate over $9 B in annual sales (^[7]). Notably, credit rating agencies assign Biogen investment-grade ratings (S&P rates Biogen BBB+ (^[7])), reflecting its moderate leverage, high barriers to entry, and strong profitability in line with large pharma peers (^[7]).

Bryce Paul's #1 Altcoin Pick

Platform powering billions in loans—priced low, used daily. Act while it's cheap.

Only $3

$97

Guide + strategic entry points & quick checklist

Grab Instant Access

90-day unconditional refund — test the playbook risk-free

Interest Coverage: Biogen’s earnings comfortably cover its interest obligations. Interest expense in the first half of 2025 was $132.6 million (^[6]), a modest figure relative to operating cash flow and profit. Even after the new 2025 notes issuance (with higher coupons up to 6.45%), annual interest cost (~$250–300 M) remains a small fraction of Biogen’s EBITDA. For context, Biogen earned $16.47 per share in 2024 (about $2.4 B net income) (^[5]), implying interest consumed only around 10% of operating profit – a 10× or higher interest coverage ratio. Management acknowledges interest expense will rise going forward due to the new debt, but this increase is expected to be “largely leverage neutral” (^[7]) and easily serviced by Biogen’s cash flows. In short, debt service coverage is strong, and Biogen’s fixed-charge obligations are well-covered by earnings, which supports its investment-grade credit profile. This financial flexibility gives Biogen room to continue investing in R&D and strategic initiatives despite carrying some debt.

Valuation and Comparables: After a steep stock decline in 2024, Biogen trades at a conservative valuation. Shares fell nearly 40% in 2024 (^[5]) amid pipeline setbacks and investor skepticism, bringing the stock down to the mid-$150s–$160 range. At ~$160 per share and with ~$16–16.5 adjusted EPS, Biogen’s trailing price-to-earnings (P/E) multiple is under 10 (^[5]). This is a discount to the broader biotech/pharma industry, where large-cap peers often trade at mid-teens earnings multiples. Even on a forward basis, with 2025 EPS guided at $15.25–16.25 (^[5]), Biogen’s forward P/E is ~10x – suggesting a low valuation relative to its growth potential. The market’s caution stems from Biogen’s flat-to-declining recent revenues and uncertainties about new drug uptake. However, if Biogen’s new launches (Leqembi, Skyclarys for ataxia, Zurzuvae for depression, etc.) ramp up and stabilize total revenue, there could be multiple expansion. Biogen’s PEG ratio (price/earnings-to-growth) is potentially attractive given a depressed stock and a pipeline of promising therapies (one analysis pegged Biogen’s PEG near 0.6, indicating undervaluation) (^[8]). Additionally, Biogen’s enterprise value to EBITDA is reasonable for its sector. The lack of a dividend may repel income investors, but it also means all earnings are reinvested or available for buybacks and deals – which, if productive, could reward shareholders via stock appreciation. Overall, the current valuation reflects investor skepticism, but also provides upside if Biogen can execute on growth initiatives.

GPU

Not About AI — About the Engine Under It

Parallel chips, racks, and power will remake everything. Learn the three secret partners and the keystone company for SMRs.

Get the Deep Dive — $199
See the 3 Secret Partners

Risks and Red Flags: Despite the optimism around new products, Biogen faces significant risks and challenges:

– Declining Legacy Franchise: Biogen’s core multiple sclerosis (MS) and spinal muscular atrophy drugs are in decline. Sales of MS therapies (like Tecfidera and Tysabri) and SMA drug Spinraza fell ~8% in recent periods due to generics and competition (^[5]) (^[9]). Tecfidera has lost exclusivity (multiple generics are on the market (^[9])), and Tysabri now faces biosimilars in Europe (with a U.S. launch expected by 2024) (^[9]). Spinraza is slowing as new SMA treatments (Novartis’s gene therapy and Roche’s Evrysdi) capture patients (^[9]). These legacy product declines pressure Biogen’s revenues (down 3.3% in H1 2024 (^[9])) and could continue for years, creating a headwind to growth.

– Pipeline and Launch Execution: While Biogen finally has an approved Alzheimer’s drug in Leqembi, it bungled the rollout of Aduhelm (its first Alzheimer’s drug) in 2021. Aduhelm’s controversial approval without clear clinical benefit led to minimal uptake and a reputational hit (^[9]). This highlights pipeline risk – many of Biogen’s R&D bets (especially in Alzheimer’s) have failed historically. The commercial execution risk is also high: even promising drugs need effective marketing and patient access. For Leqembi, initial uptake was “slow” in early 2023, though it improved after full approval and Medicare reimbursement (^[9]). Similarly, Biogen’s new Zurzuvae (zuranolone) for postpartum depression and Skyclarys (acquired from Reata) for Friedreich’s ataxia are in very early launch phases (^[9]). There is no guarantee these will meet sales expectations, and any missteps or safety issues could hamper adoption.

– Regulatory and Safety: High‐profile drugs like Leqembi carry safety warnings (risk of ARIA brain edema and bleeds (^[1])), requiring careful patient monitoring. Any serious adverse events could limit use. Regulatory scrutiny is intense in Alzheimer’s – future label expansions or competitors’ approvals could change the landscape quickly. Competitor Eli Lilly is seeking approval for donanemab (its Alzheimer’s antibody), which could become a formidable rival. Biogen’s North America head acknowledged that Leqembi’s near-term U.S. growth will likely be “linear” (steady but not explosive) (^[10]), and competition could stiffen by late 2024 or 2025 if Lilly’s drug hits the market. Biogen will need to differentiate Leqembi and possibly develop new dosing (e.g. maintenance or subcutaneous forms) (^[11]) to stay ahead.

– Legal and Intellectual Property: Biogen occasionally faces IP litigation and royalty disputes. For instance, a court recently ruled Biogen owes Genentech $88 M in royalties related to Tysabri’s manufacturing patents (^[12]). While not financially crippling for Biogen, it underscores the patent tangles common in biotech. Upcoming patent cliffs (e.g. Biogen’s Ocrevus royalty from Roche’s MS drug could wane when biosimilars arrive by 2030 (^[13])) are a concern. Any erosion of patent protection for current or pipeline drugs is a red flag for future revenue.

– Financial and M&A Execution: Biogen’s aggressive M&A strategy carries risk. The $6.5 B Reata acquisition in 2023 adds leverage and integration challenges (^[5]). There is a risk that Biogen overpays or fails to realize hoped-for benefits from deals (e.g., its partnership with Sage saw a setback when depression drug Zulresso underperformed). While CEO Chris Viehbacher is reining in M&A for now, stating he sees “no burning need” for more big acquisitions (^[14]), Biogen’s growth plan still involves external innovation. If new acquisitions or collaborations are needed and they misfire, it could destroy value. Additionally, Biogen’s cost-cutting (a $1 B savings program (^[5])) must be balanced against the need to invest in R&D under-investment could hurt long-term innovation.

Valuation Drivers & Outlook: The bull case for Biogen rests on new drugs filling the revenue gap. Management is “convinced the worst is over” for Leqembi’s rollout and expects steady uptake ahead (^[15]). Leqembi, Skyclarys, and Zurzuvae all “exceeded…internal expectations” in early launches (^[9]), and Biogen projects that new product revenues will surpass current drug sales by 2028 (^[14]). If this materializes, Biogen could return to growth and earn a higher valuation multiple. The bear case, however, points to a possibility that new launches won’t grow fast enough to offset the decline of the aging MS franchise, especially with looming competition in Alzheimer’s and neuroscience. Investors also remain wary after the stock’s rough 2024, needing proof that Biogen can stabilize its top line.

Open Questions and Uncertainties: Several key questions remain open for Biogen’s investment thesis:

– Will Leqembi become a true blockbuster? Its inclusion in TIME’s Best Inventions highlights its potential, but can Biogen and Eisai educate physicians, scale infusion capacity, and navigate safety monitoring to achieve multi-billion dollar sales? Uptake has begun, yet the Alzheimer’s market is uncharted – how fast will diagnoses and treatment increase, and will insurers fully support the costly therapy?

– How will competition impact Alzheimer’s franchise? Eli Lilly’s donanemab (pending FDA decision) could compete directly with Leqembi. Can Biogen maintain an edge through first-mover advantage and better dosing strategies (e.g. maintenance dosing or a planned auto-injector version) (^[11])? The Alzheimer’s space may eventually accommodate multiple drugs, but pricing pressure and market share battles loom.

– Can new launches offset declines in time? Biogen is betting on rare disease and niche neurology drugs like Skyclarys (Friedreich’s ataxia) and Zurzuvae (postpartum depression) for growth (^[9]) (^[9]). These markets are smaller than Alzheimer’s or MS. Will their sales ramp up quickly enough, and are there other pipeline assets (e.g. BIIB080 for neurodegenerative disease (^[14])) that could surprise to the upside? The timeline to 2028 (when new product revenue is expected to surpass old (^[14])) is several years – investors will be watching each quarter to judge if Biogen is on track or if the gap is widening.

– What is Biogen’s long-term strategy on capital allocation? With no dividend, will Biogen consider initiating one if cash flows grow (as some have urged in the past), or will it stick to reinvestment and occasional buybacks? Also, having pulled off a big acquisition (Reata) and smaller deals, can Biogen drive synergies from these or will it be forced to pursue additional M&A to stay competitive (e.g. in gene therapy or oncology)? The CEO’s current stance is to focus internally (^[14]), but strategic pivots are always possible in biotech.

In summary, Biogen today presents a turnaround story: a once-dominant biotech facing declines in its legacy portfolio but armed with TIME-lauded innovation and a refreshed pipeline that could reignite growth. The company’s financial foundation – no dividend, moderate debt, strong interest coverage, and ongoing cost discipline – gives it the flexibility to execute on this turnaround. However, investors need evidence that Biogen’s new inventions (like Leqembi) truly have commercial legs. If Biogen delivers on the promise of these “extraordinary innovations” in the coming years, the currently low valuation and depressed stock could indeed skyrocket. Conversely, failure to capitalize on its best inventions, or new competitive/regulatory hurdles, would leave Biogen languishing. The next few quarters and clinical milestones will be crucial in determining which path BIIB takes. The opportunity is big, but so are the challenges – making Biogen a high-stakes equity story to watch closely.

Sources: Biogen Investor Relations; SEC 10-Q filings; TIME; Reuters; Zacks/Nasdaq; Motley Fool; Investing.com; CNBC. All financial and operational data sourced from company filings and reputable financial news (^[3]) (^[6]) (^[2]) (^[5]), with background on drug approvals and pipeline from industry reports (^[1]) (^[9]). All statements and statistics are backed by the cited sources.

Sources

For informational purposes only; not investment advice.